Asia Dengue Voice & Action Group (ADVA)
The Asian Dengue Vaccine Advocacy (ADVA) is a scientific working group dedicated to
dengue vaccine advocacy in Asia, with the aim of disseminating information and making
recommendations on dengue vaccine introduction strategies in Asia.
Set up in 2011, ADVA’s mission is to identify opportunities and make practical
recommendations for improving surveillance and laboratory capacity for dengue disease
confirmation, including documenting and standardising existing systems and coverage,
standardising case confirmation and diagnostics, selecting initial target groups for
vaccination, addressing programme feasibility by improving existing infrastructure (cold
chain, pharmacovigilance, vaccination compliance monitoring, and vaccine supply and
distribution logistics), preparing and implementing a risk management plan, collaborating
with other relevant dengue initiatives including V2V (vaccine to vaccination) and the
Dengue Vaccine Initiative.
The value of the ADVA initiative lies in its collaborative approach to sharing surveillance
data and relevant information, which are important in ensuring the success of the
Dengue disease prevention through vaccination.
ADVA also reinforces the importance of a united front against dengue and presents a
collaborative model for joint effort in the region focused on the prevention of the disease
through the introduction and implementation of dengue vaccination.
The group has formulated recommendations with an ultimate aim of translating the
science of dengue vaccination into messages for policy makers, general public and
health care workers.
Global Dengue and Aedes-transmitted Diseases Consortium (GDAC)
Four leading institutions at the forefront of dengue prevention and control—the
International Vaccine Institute (IVI), the International Vaccine Access Center (IVAC) of
the Johns Hopkins University, the Partnership for Dengue Control Foundation (PDC) and
the Sabin Vaccine Institute have formed a new global alliance, which is named the
Global Dengue and Aedes-transmitted Diseases Consortium (GDAC). This new
partnership will integrate approaches to fight dengue and other Aedes-transmitted
diseases including Zika, chikungunya and yellow fever.
GDAC will be working closely with the World Health Organization (WHO) to provide
scientific evidence to facilitate comprehensive Aedes-transmitted disease control,
incorporating research and public health projects, technical meetings and consultancies,
regulatory and policy support, financing frameworks and communications and advocacy.
The key objectives of this alliance is to accelerate innovation and application of
vaccines, vector control, antivirals, clinical management, therapeutics, diagnostics and
surveillance, and licensure and post-marketing oversight of vaccines. In addition, GDAC
will focus on strengthening social mobilization, advocacy and capacity building. It will
continue its members’ work with vaccine early adopter countries to develop integrated
control strategies specific to those countries. GDAC will work with all stakeholders to
develop strategies designed to prevent outbreaks caused by other viruses transmitted
by Aedes mosquitoes. With its global presence in Asia, America and Europe, GDAC will
build a common agenda to lead the new era of Aedes-transmitted diseases prevention
SEAMEO TROPMED Network
SEAMEO TROPMED Network is the regional cooperation network for education, training
and research in tropical medicine and public health, which is parked under the
Southeast Asian Ministers of Education. The Network aims to become and international
forum for development in health and is working towards developing the capacity of
institutions and individuals in delivering quality healthcare. This network serves as a
focal point in higher education and research in tropical medicine and public health.
The objectives of SEAMEO TROPMED are centred on training healthcare workers,
supporting research on endemic and emerging diseases and advocating relevant health
policies in order to empower communities with knowledge and encourage the use of
tools for disease prevention thus minimizing the economic burden of health.
Fondation Merieux (FMx)
The Mérieux Fondation is an independent family foundation with public interest status
and is committed to fighting, in the field, the infectious diseases that affect developing
countries by building capacities, particularly in clinical laboratories.
With its network of laboratories, the foundation’s work is focused on diagnosis, an
essential aspect of patient care and an indispensable tool for disease surveillance and
control. Taking a global health approach, the foundation also works in the field to help
the most vulnerable, with a strong emphasis on mothers and children.
The Mérieux Fondation help the most vulnerable populations, particularly mothers and
children, gain fairer access to healthcare. From its very beginning in 1967, the Mérieux
Fondation has united public and private sector partners around a common mission.
Active today in over twenty countries, the Foundation works to strengthen the skills of
healthcare professionals in the field to ensure its programs have a long-lasting impact. It
catalyzes local and international initiatives to help the most vulnerable populations gain
fairer access to healthcare.
The Mérieux Foundation works closely with Fondation Christophe et Rodolphe Mérieux,
an independent family foundation under the aegis of the Institut de France, sharing the
same public health goals.